ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly neuroscience — Worldwide revenue ($M) [legacy total] ($M)
Form 10-Q / 10-K Note 2
Latest, FY2017
2,171
Period ended Dec 31, 2017
Change on a year earlier
-20.2%
2,720 in FY2016
History
7 years
Since FY2011
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Neuroscience — Worldwide revenue ($M) [legacy total] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2017 | Dec 31, 2017 | 2,171 | -20.2% | Form 10-K (filed 2018-02-20) ↗ |
| FY2016 | Dec 31, 2016 | 2,720 | -7.3% | Form 10-K (filed 2018-02-20) ↗ |
| FY2015 | Dec 31, 2015 | 2,935 | -18.4% | Form 10-K (filed 2016-02-19) ↗ |
| FY2014 | Dec 31, 2014 | 3,597 | -50.2% | Form 10-K (filed 2015-02-19) ↗ |
| FY2013 | Dec 31, 2013 | 7,216 | -4.7% | Form 10-K (filed 2014-02-19) ↗ |
| FY2012 | Dec 31, 2012 | 7,575 | -22.1% | Form 10-K (filed 2014-02-19) ↗ |
| FY2011 | Dec 31, 2011 | 9,724 | – | Form 10-K (filed 2014-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Neuroscience — Worldwide revenue ($M) [legacy total] ($M), annual FY2011–FY2017 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta_neuroscience_ww_legacy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.